` CGEM (Cullinan Oncology Inc) vs S&P 500 Comparison - Alpha Spread

CGEM
vs
S&P 500

Over the past 12 months, CGEM has underperformed S&P 500, delivering a return of -18% compared to the S&P 500's +14% growth.

Stocks Performance
CGEM vs S&P 500

Loading
CGEM
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CGEM vs S&P 500

Loading
CGEM
S&P 500
Difference
www.alphaspread.com

Performance By Year
CGEM vs S&P 500

Loading
CGEM
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cullinan Oncology Inc vs Peers

S&P 500
CGEM
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cullinan Oncology Inc
Glance View

Market Cap
571.9m USD
Industry
Biotechnology

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

CGEM Intrinsic Value
Not Available
Back to Top